CD20+CD204+

Qinyang Chen1, Jian Zhang1, Jianwei Feng2

  • 1The Academy of Chinese Health Risks, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in oncology
|December 4, 2025
PubMed
概括

瘤透免疫细胞 (TIIC) 影响胸膜上皮瘤 (TETs) 的存活率. 高CD20+ TIIC改善了结果,而CD204+ TIIC表明预后较差,这表明M2巨细胞向更好的TETs治疗.